Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bristol mail room mishap permitted Geneva generic captopril approval -- BMS testimony.

Executive Summary

BRISTOL MAIL ROOM ERROR ALLOWED GENEVA CAPTOPRIL APPROVAL, Bristol outside counsel Robert Baechtold of the New York City firm Fitzpatrick, Cella, Harper & Scinto indicated during a Nov. 11 hearing before Newark, N.J. federal court Judge John Lifland. "Because Geneva's certification was never delivered to anybody at Bristol who was responsible for captopril, we didn't know about it, we didn't sue them. If we had sued them, they certainly would not be in the market today," he asserted.

You may also be interested in...



Pfizer Norvasc Challenges: Mylan ANDA, Dr. Reddy’s 505(b)(2)

Pfizer's Norvasc patent suit against Mylan could still delay the launch of Mylan's generic amlodipine, despite the lack of a 30-month stay

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

Latest Headlines
See All
UsernamePublicRestriction

Register

PS027296

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel